Pain‐free response at 2 h for moderate to severe baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
High
Headache relief at 2 h for moderate to severe baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
High
Sustained pain‐free during the 24 h post dose for moderate to severe baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Sustained headache relief during the 24 h post dose for moderate or severe baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
High
At least 1 AE during treatment for moderate to severe baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Patient Global Impression of Change · adults with neuropathic pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient Global Impression of Change much or very much improved · adults with fibromyalgia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Participant‐reported pain relief of 30% or greater · adults with fibromyalgia
Mirtazapine may leads to higher participant‐reported pain relief of 30% or greater (moderate… compared with placebo (low certainty).
1 finding from 1 review
Moderate benefit · adults with postherpetic neuralgia
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
IMMPACT definition ‐ any at least moderate pain benefit · adults with postherpetic neuralgia
1 finding from 1 review
Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved · people with diabetic peripheral neuropathy
1 finding from 1 review
Any pain‐related outcome (moderate pain improvement) · adults with neuropathic pain
It is very uncertain whether morphine changes any pain‐related outcome (moderate pain improvement) compared with placebo (very low certainty).
1 finding from 1 review
Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved · adults with fibromyalgia
It is very uncertain whether NSAID changes moderate pain relief: at least 30% reduction in pain, or PGIC much… compared with placebo (very low certainty).
1 finding from 1 review
Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved · adults with chronic neuropathic pain
1 finding from 1 review
Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved · adults with neuropathic pain (2 studies in peripheral diabetic neuropathy and 1 study in postherpetic neuralgia)
1 finding from 1 review
Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved · adults with chronic neuropathic pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Moderate benefit: at least 30% reduction in pain, or PGIC much or very much improved · Adults with chronic neuropathic pain
1 finding from 1 review
At least 30% reduction in pain · adults with fibromyalgia
1 finding from 1 review
Moderate benefit · adults with fibromyalgia
1 finding from 1 review
Maintenance of initial therapeutic response of at least 30% pain intensity reduction over baseline and continued treatment at 13 or 26 weeks (equivalent to 'moderate benefit') · adults with fibromyalgia enrolled in EERW studies
1 finding from 1 review